NCT00344981 (HADIT) is a NA clinical trial of Tenofovir in HIV Infections, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT00344981?

NCT00344981 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT00344981?

Interventions in NCT00344981: Tenofovir, Hydroxyurea.

What condition does NCT00344981 study?

NCT00344981 studies HIV Infections, AIDS.

Is NCT00344981 still recruiting?

NCT00344981 is currently completed. Last updated 6 May 2021.

Last reviewed 2021-05-06 · How we verify

NCT00344981: HADIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Probe The Safety And Durability of Tenofovir And a Cell Cycle Agent to Maintain Viral Suppression

Completed NA Last updated 6 May 2021

What this trial tests

NA trial testing Tenofovir in HIV Infections in 9 participants. Completed in 1 November 2006.

Timeline

1 June 2003

Primary endpoint
1 November 2006

1 November 2006

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 June 2003
Primary completion	1 November 2006
Estimated completion	1 November 2006
Sites	1 location across United States

Drugs / interventions tested

Tenofovir — full drug profile →
Hydroxyurea — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →
AIDS — all drugs for AIDS →

Sponsor

University of Maryland, Baltimore

Who can join

18 and older, any sex, with HIV Infections or AIDS. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Loss of viral suppression during maintenance therapy, defined by 3 consecutive viral load measurements greater than 50c/ml over a 48- week period.
Time frame: At any point during the 48 week study
Viral load measurements will be done throughout the study to monitor for viral suppression

Sponsor's own description

Study Hypothesis Evaluation of the durability of the combination Tenofovir and Hydroxyurea to maintain viral suppression below 50 copies/ml in volunteers who have achieved viral suppression on a standard HAART regimen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tenofovir

Trials testing the same drug.

NCT06295328 — From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients · Phase 1, PHASE2 · recruiting
NCT02650271 — Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC · Phase 3 · completed
NCT04539119 — Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA · Phase 3 · unknown
NCT04431375 — Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy · NA · unknown
NCT03986970 — The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention · Phase 2 · completed

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00344981 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 6 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00344981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing